论文部分内容阅读
目的探讨新辅助化疗用于乳腺癌对患者血清GDF3、TK1、CA15-3和CEA水平的影响。方法将220例乳腺癌患者随机分为研究组和对照组各110例。研究组采用新辅助化疗联合保乳手术治疗,对照组采用单纯保乳手术治疗。观察2组治疗前后血清DF3、TK1、CA15-3和CEA水平。结果治疗前2组血清GDF3、TK1、CA15-3和CEA水平差异无统计学意义(P>0.05)。2组治疗后血清GDF3、TK1、CA15-3及CEA水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。结论新辅助化疗联合保乳手术治疗乳腺癌较单纯保乳手术治疗可更有效地降低血清GDF3、TK1、CA15-3和CEA水平。
Objective To investigate the effect of neoadjuvant chemotherapy on the serum levels of GDF3, TK1, CA15-3 and CEA in patients with breast cancer. Methods 220 cases of breast cancer were randomly divided into study group and control group of 110 cases. The study group was treated with neoadjuvant chemotherapy and breast-conserving surgery while the control group was treated with simple breast-conserving surgery. The levels of serum DF3, TK1, CA15-3 and CEA in two groups before and after treatment were observed. Results There was no significant difference in serum GDF3, TK1, CA15-3 and CEA levels between the two groups before treatment (P> 0.05). The levels of serum GDF3, TK1, CA15-3 and CEA in the two groups after treatment were lower than those before treatment, and the difference between the two groups was statistically significant (P <0.05). Conclusion Neoadjuvant chemotherapy combined with breast-conserving surgery for breast cancer can lower serum GDF3, TK1, CA15-3 and CEA levels more effectively than simple breast-conserving surgery.